Irbesartan was renoprotective in patients with type 2 diabetes, hypertension, and microalbuminuria
- Prevalence of microalbuminuria and risk factor analysis in type 2 diabetes patients in Albania: the need for accurate and early diagnosis of diabetic nephropathy. Pasko, N.; Toti, F.; Strakosha, A.; Thengjilli, E.; Shehu, A.; Dedej, T.; Ylli, A.; Thereska, N. // Hippokratia;2013, Vol. 17 Issue 4, p337
Background: Microalbuminuria is often the first sign of renal dysfunction in diabetes. This study aimed to investigate the prevalence of microalbuminuria in Albanian type 2 diabetes patients and its association with other cardiovascular risk factors. Methods: Three hundred and twenty-one...
- Four studies find linagliptin effective as monotherapy, add-on in adults with type 2 diabetes. Costa, Samantha; Fisher, Stacey L.; Foster, Melissa // Endocrine Today;Nov2012, Vol. 10 Issue 11, p36
The article reports on four studies which found that linagliptin administered alone or in combination with other diabetes medications, and as an add-on to basal insulin therapy is effective in adults with type 2 diabetes and diabetic nephropathy.
- The Effect of Milk Thistle Extract in the Treatment of Diabetic Nephropathy. Rezvanian, Hassan; Kachuei, Ali; Mirzapour, Ali // Journal of Isfahan Medical School;3/28/2011, Vol. 28 Issue 124, p1
Background: Milk thistle has antioxidative effects and may improve renal performance. Our study investigated whether Milk thistle improve renal performance in patients with type II diabetes mellitus nephropathy. Methods: In this clinical trial study, after ethics committee approval, 65 Patients...
- Periostin as a Tissue and Urinary Biomarker of Renal Injury in Type 2 Diabetes Mellitus. Satirapoj, Bancha; Tassanasorn, Surat; Charoenpitakchai, Mongkon; Supasyndh, Ouppatham // PLoS ONE;Apr2015, Vol. 10 Issue 4, p1
Background: Improving the early detection of diabetic nephropathy remains a great challenge in disease management. Periostin is a marker of renal tubular injury and related to progressive kidney injury in animal models of chronic kidney disease. The clinical implications of urinary periostin...
- Limitations of HbA[sub1c] in diabetes control. // Pulse;3/24/2003, Vol. 63 Issue 12, p88
Discusses the limitations of the HbA[sub 1c] in aiding the treatment of type 2 diabetes. Method of monitoring the effectiveness of therapy in diabetes; Clinical advantages of measuring fructosamine level.
- New diabetes treatments may be on horizon. // Diabetes in the News;Nov/Dec94, Vol. 13 Issue 6, p3
Reports on studies regarding new therapies for type II diabetes. Food and Drug Administration's (FDA) pending approval of an oral agent called metformin; Studies on thiazoles and vanadates; Mechanism of action of tolrestat; Use of combination drug approach in diabetes-related impotence; Use of...
- Exenatide LAR: A sustained-release formulation of exenatide for the treatment of type 2 diabetes. // Formulary;Feb2010, Vol. 45 Issue 2, p34
An abstract of the article "Exenatide LAR: A sustained-release formulation of exenatide for the treatment of type 2 diabetes," by Ashley Krause and Jennifer Kirwin is presented.
- Managing Obesity as First-Line Therapy for Diabetes Mellitus. Kelley, David E. // Nutrition in Clinical Care;Jan/Feb98 Supplement 1, Vol. 1 Issue 1, p38
Focuses on the management of obesity for the treatment of type 2 diabetes mellitus in the United States. Improvement of weight loss in obese patients; Impact of weight loss on the clinical efficacy of concominant pharmacologic therapy; Reduction of skeletal muscles insulin resistance.
- Newer, controlled-release glipizide is superior to its conventional form. // Modern Medicine;Mar95, Vol. 63 Issue 3, p53
Presents an abstract of the article `Comparative Efficacy of a Once-daily Controlled-Release Formulation of Glipizide and Immediate-Release Glipizide in Patients With NIDDM,' by M. Berelowitz, C. Fischette et al dated December 1994.